Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Mavacamten: A Review of a Novel Therapeutic Approach for Hypertrophic Cardiomyopathy
View through CrossRef
Hypertrophic Cardiomyopathy (HCM) is a heart disease that can cause left ventricular
hypertrophy, arrhythmias, heart failure, and sudden cardiac death. Currently, pharmacological
treatment is limited and ineffective. Mavacamten (Camzyos<sup>TM</sup>) is a cardiac myosin inhibitor developed
as a therapeutic option to reduce myocardial contractility and restoration of myocardial
function. The Food and Drug Administration (FDA) approved the use of Mavacamten in 2022
for HCM symptoms. Clinical studies have proven that Mavacamten can reduce Left Ventricular
Outflow Tract (LVOT) involvement, cardiac hypercontraction, and hypertrophy. This review
provides an overview of HCM, its pathophysiology, current treatments, synthesis of Mavacamten,
and the clinical trials of Mavacamten.
Bentham Science Publishers Ltd.
Title: Mavacamten: A Review of a Novel Therapeutic Approach for Hypertrophic Cardiomyopathy
Description:
Hypertrophic Cardiomyopathy (HCM) is a heart disease that can cause left ventricular
hypertrophy, arrhythmias, heart failure, and sudden cardiac death.
Currently, pharmacological
treatment is limited and ineffective.
Mavacamten (Camzyos<sup>TM</sup>) is a cardiac myosin inhibitor developed
as a therapeutic option to reduce myocardial contractility and restoration of myocardial
function.
The Food and Drug Administration (FDA) approved the use of Mavacamten in 2022
for HCM symptoms.
Clinical studies have proven that Mavacamten can reduce Left Ventricular
Outflow Tract (LVOT) involvement, cardiac hypercontraction, and hypertrophy.
This review
provides an overview of HCM, its pathophysiology, current treatments, synthesis of Mavacamten,
and the clinical trials of Mavacamten.
Related Results
Is mavacamten superior to aficamten for hypertrophic cardiomyopathy? A frequentist network meta-analysis
Is mavacamten superior to aficamten for hypertrophic cardiomyopathy? A frequentist network meta-analysis
Background: Myosin inhibitors have been shown to improve exercise capacity and symptoms, as well as reduce the left ventricular outflow tract (LVOT) gradient. This study explores t...
Abstract 4144404: Efficacy of Mavacamten on Echocardiographic Parameters and Cardiac Biomarkers in Hypertrophic Cardiomyopathy Patients: A Systematic Review and Meta-Analysis
Abstract 4144404: Efficacy of Mavacamten on Echocardiographic Parameters and Cardiac Biomarkers in Hypertrophic Cardiomyopathy Patients: A Systematic Review and Meta-Analysis
Introduction:
Mavacamten, a cardiac myosin inhibitor, distinguishes from other pharmacological interventions by addressing not only symptomatic treatment but also targe...
Drug–Drug Interaction Potential of Mavacamten with Midazolam: Combined Results from Clinical and Model‐Based Studies
Drug–Drug Interaction Potential of Mavacamten with Midazolam: Combined Results from Clinical and Model‐Based Studies
AbstractMavacamten is a potential inducer of cytochrome P450 (CYP) 3A4 and could reduce the effectiveness of concomitant drugs that are metabolized by CYP3A4, such as midazolam. Th...
Diagnostic capabilities of cardiac computed tomography in the preoperative diagnosis of hypertrophic cardiomyopathy
Diagnostic capabilities of cardiac computed tomography in the preoperative diagnosis of hypertrophic cardiomyopathy
BACKGROUND: A comprehensive approach to studying hypertrophic cardiomyopathy with diagnostic equipment and the latest scanning methods will ensure quality control and effective tre...
Comparative Analysis of the Coronary Arteries Flow Pattern in Secondary Myocardial Hypertrophies and by Sarcomeric Mutation
Comparative Analysis of the Coronary Arteries Flow Pattern in Secondary Myocardial Hypertrophies and by Sarcomeric Mutation
Background: Coronary flow with a diastolic predominance increases two to five times in hyperemia, mediated by vasodilation (coronary flow reserve, CFR) and, in hypertrophy, relativ...
MAVACAMTEN NO TRATAMENTO DA CARDIOMIOPATIA HIPERTRÓFICA
MAVACAMTEN NO TRATAMENTO DA CARDIOMIOPATIA HIPERTRÓFICA
Introdução: A cardiomiopatia hipertrófica (CMH) é uma das doenças cardíacas genéticas mais comuns, afetando entre 0,16% e 0,29% da população adulta geral. É uma doença genética do ...
Abstract 4362395: Efficacy of Mavacamten Combined with Standard Therapy in Hypertrophic Obstructive Cardiomyopathy: A Retrospective Cohort Study
Abstract 4362395: Efficacy of Mavacamten Combined with Standard Therapy in Hypertrophic Obstructive Cardiomyopathy: A Retrospective Cohort Study
Background:
Hypertrophic obstructive cardiomyopathy (HOCM) is usually treated with standard therapy: beta-blockers (BBs) and/or non-dihydropyridine calcium chan...
Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy
Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy
Hypertrophic cardiomyopathy is the most common monogenic cardiovascular disease that is caused by sarcomeric protein gene mutations. A hallmark of the most common form of the disea...